Patent application number | Description | Published |
20090195977 | DATA CENTER COOLING - A system for restricting mixing of air in a data center includes a plurality of racks, each of the racks having a front face and a back face. The system includes an enclosure for collecting air released from the back faces of the plurality of racks, the enclosure configured to substantially contain the air in an area between the first row and the second row and having a roof panel coupled to the first row of racks and the second row of racks configured to span a distance between the first row of racks and the second row of racks. The enclosure is configured to maintain a first air pressure inside of the enclosure that is substantially equal to a second air pressure outside the enclosure. | 08-06-2009 |
20100165572 | DATA CENTER COOLING - A system for restricting mixing of air in a data center includes a plurality of racks, each of the racks having a front face, and a back face. The system includes an enclosure for collecting air released from the back faces of the plurality of racks, the enclosure configured to substantially contain the air in an area between the first row and the second row and having a roof panel coupled to the first row of racks and the second row of racks configured to span a distance between the first row of racks and the second row of racks. The enclosure is configured to maintain a first air pressure inside of the enclosure that is substantially equal to a second air pressure outside the enclosure. | 07-01-2010 |
20110103014 | Data Center Cooling - A system for restricting mixing of air in a data center includes a plurality of racks, each of the racks having a front face and a back face. The system includes an enclosure for collecting air released from the back faces of the plurality of racks, the enclosure configured to substantially contain the air in an area between the first row and the second row and having a roof panel coupled to the first row of racks and the second row of racks configured to span a distance between the first row of racks and the second row of racks. The enclosure is configured to maintain a first air pressure inside of the enclosure that is substantially equal to a second air pressure outside the enclosure. | 05-05-2011 |
20120231722 | DATA CENTER COOLING - A system for restricting mixing of air in a data center includes a plurality of racks, each of the racks having a front face and a back face. The system includes an enclosure for collecting air released from the back faces of the plurality of racks, the enclosure configured to substantially contain the air in an area between the first row and the second row and having a roof panel coupled to the first row of racks and the second row of racks configured to span a distance between the first row of racks and the second row of racks. The enclosure is configured to maintain a first air pressure inside of the enclosure that is substantially equal to a second air pressure outside the enclosure. | 09-13-2012 |
Patent application number | Description | Published |
20080317728 | Lowering Uric Acid to Prevent or Accelerate Recovery of Acute Renal Failure - Disclosed herein are methods of preventing acute renal failure, ARF, as well as treating and accelerating the recovery of patients experiencing ARF. The inventors believe that an elevated serum uric acid, either occurring at baseline in the patient, or being brought about post-operatively is a major factor leading to ARF. Specifically exemplified are methods that involve administering to a patient at risk of experiencing ARF a composition comprising a uric acid lowering agent. | 12-25-2008 |
20090312415 | Remedy/preventive for vascular disorders and hypertension and method of screening the same - It is intended to clarify a transportation system participating in the uric acid uptake in vascular smooth muscle cells (VSMCs) and provide a novel remedy, a preventive or a treating agent for vascular disorders, hypertension and renal disorders with the use of a drug participating in this transportation system. It is also intended to provide a novel screening system for a remedy, a preventive or a treating agent for vascular disorders, hypertension and renal disorders with the use of such a transportation system. Namely, a medicinal composition for healing, preventing or treating vascular disorders, hypertension and renal disorders which comprises a drug having an effect of inhibiting the uric acid uptake by a uric acid transporter URAT1 and a pharmaceutically acceptable carrier; and a method of screening a substance efficacious for healing, preventing or treating vascular disorders, hypertension and renal disorders which comprises using a cell line expressing URAT1 in the presence or absence of a test compound and assaying the uric acid uptake level, cell proliferation ability or the amount of a monocyte chemotactic factor produced by the cells. | 12-17-2009 |
20100120796 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUNECES - Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl. | 05-13-2010 |
20120220607 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUENCES - Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl. | 08-30-2012 |